Antidepressant Drugs

Correct Answer

C — Cyproheptadine

Rationale

Cyproheptadine is classified as the pharmacological treatment for moderate serotonin syndrome. It is a histamine H1 antagonist that also has serotonin-2A receptor blocking activity, which directly reduces serotonergic receptor stimulation at the central and peripheral receptors responsible for the clinical triad. Dantrolene is used in malignant hyperthermia and sometimes in neuroleptic malignant syndrome, but is not indicated for serotonin syndrome because the mechanism of hyperthermia differs. Bromocriptine is a dopamine agonist used in neuroleptic malignant syndrome. Physostigmine is a cholinesterase inhibitor used for anticholinergic toxidrome, not for serotonin syndrome.

Correct Answer

A — Linezolid

Rationale

Linezolid is an oxazolidinone antibiotic that carries monoamine oxidase A inhibitory activity as a secondary pharmacological property in addition to its antibacterial mechanism. This classification places it in the same functional category as phenelzine and tranylcypromine when co-administered with serotonergic drugs. When a patient taking a selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor requires linezolid, the antidepressant must be switched before linezolid can be safely started. Ciprofloxacin inhibits cytochrome P450 1A2 but does not have monoamine oxidase inhibitory activity. Azithromycin and vancomycin do not have clinically relevant monoamine oxidase inhibitory or serotonergic pharmacological properties.

Correct Answer

D — Sertraline

Rationale

Sertraline has the lowest relative infant dose among the selective serotonin reuptake inhibitors and is the preferred first-choice antidepressant during breastfeeding. Relative infant dose is the infant's weight-adjusted dose as a percentage of the maternal weight-adjusted dose — for sertraline this is consistently low across published studies. Fluoxetine has a higher relative infant dose due to its active metabolite norfluoxetine, which has a long half-life in neonates, and is generally avoided during breastfeeding when an alternative is available. Paroxetine also has a low relative infant dose and is an acceptable alternative, but sertraline has the most favorable data overall. Citalopram carries a higher relative infant dose than sertraline and is not the preferred agent during lactation.

Correct Answer

B — Paroxetine

Rationale

Paroxetine carries the most cautious pregnancy labeling among the selective serotonin reuptake inhibitors based on earlier signals of a possible association with ventricular septal defects and other cardiovascular malformations in neonates exposed during the first trimester. Although subsequent larger studies have not consistently replicated this finding, paroxetine remains the selective serotonin reuptake inhibitor most avoided in pregnancy when alternatives are available. Sertraline and escitalopram are the preferred selective serotonin reuptake inhibitors in pregnancy based on the most favorable available safety data. Fluvoxamine is avoided in practice for different reasons — its high cytochrome P450 drug interaction burden is the main clinical concern rather than teratogenicity.

Correct Answer

A — Escitalopram

Rationale

Escitalopram and sertraline are the preferred first-line antidepressants in elderly patients, based on favorable tolerability profiles, pharmacokinetic data in older adults, and evidence from randomized controlled trials in late-life depression. Both agents have minimal anticholinergic activity, a low risk of drug interactions from cytochrome P450 inhibition, and predictable pharmacokinetics. Amitriptyline is a tertiary amine tricyclic antidepressant listed on the Beers Criteria as potentially inappropriate for routine use in older adults because of its high anticholinergic burden and orthostatic hypotension risk. Paroxetine has anticholinergic activity and the highest discontinuation syndrome risk in the class, making it less suitable in elderly patients. Venlafaxine elevates blood pressure through norepinephrine transporter inhibition and requires monitoring in this population.

Correct Answer

D — Tramadol

Rationale

Tramadol is classified as having both opioid receptor agonist activity and serotonin reuptake transporter inhibitory activity, distinguishing it pharmacologically from pure opioid agonists such as morphine, hydrocodone, and oxycodone. This serotonin reuptake transporter inhibitory property creates a real and underrecognized risk of serotonin syndrome when tramadol is prescribed to patients already taking selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors — a combination frequently encountered in postoperative pain management. Tramadol also inhibits norepinephrine reuptake. Morphine, hydrocodone, and oxycodone are pure opioid receptor agonists without serotonin reuptake transporter activity and do not carry the same risk of precipitating serotonin syndrome through this mechanism.

Correct Answer

B — Both drugs have monoamine oxidase A inhibitory activity, creating the same dangerous combination as an antidepressant plus phenelzine

Rationale

Linezolid — an oxazolidinone antibiotic — and intravenous methylene blue — used to treat methemoglobinemia — both possess monoamine oxidase A inhibitory activity as secondary pharmacological properties. When either drug is combined with a selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor, the resulting combination functionally equivalent to pairing a serotonin reuptake inhibitor with phenelzine — blocking both serotonin reuptake and its enzymatic degradation simultaneously. This dual blockade of serotonin clearance produces rapidly rising synaptic serotonin concentrations and precipitates serotonin syndrome. When these drugs are required, the serotonergic antidepressant must be discontinued before starting them. The antidepressant should be restarted only after sufficient time has elapsed following the monoamine oxidase A inhibitor course. Neither drug blocks the serotonin reuptake transporter directly or acts as a serotonin-2A receptor agonist.

Correct Answer

C — Cyproheptadine's serotonin-2A antagonism directly reduces serotonergic receptor stimulation; dantrolene targets ryanodine receptor-mediated calcium release, which is not the mechanism of hyperthermia in serotonin syndrome

Rationale

Cyproheptadine is effective in serotonin syndrome because it is a serotonin-2A receptor antagonist — it directly blocks the receptor subtype whose overstimulation is responsible for the neuromuscular and autonomic features of the syndrome, reducing the serotonergic signal at the receptor level. Dantrolene, by contrast, acts by blocking ryanodine receptors in the sarcoplasmic reticulum of skeletal muscle, preventing pathological calcium release — the mechanism responsible for hyperthermia in malignant hyperthermia and the muscle rigidity of neuroleptic malignant syndrome. In serotonin syndrome, hyperthermia results from uncontrolled serotonin-driven muscle hyperactivity and clonus rather than from ryanodine receptor-mediated calcium dysregulation. Since dantrolene's target is not the mechanism of serotonin syndrome hyperthermia, it provides no benefit. For severe cases with temperatures above 41 degrees Celsius, neuromuscular paralysis and sedation are required to halt thermogenesis from muscle hyperactivity.

Correct Answer

A — Serotonin reuptake transporter blockade on platelets depletes their serotonin stores, impairing the serotonin-mediated platelet aggregation required for normal hemostasis

Rationale

Platelets do not synthesize serotonin but acquire it from the circulation via the serotonin reuptake transporter on their surface. They release serotonin during platelet activation, where it promotes further aggregation and contributes to hemostatic plug formation. Selective serotonin reuptake inhibitors block the serotonin reuptake transporter on platelets just as they do in neurons, progressively depleting platelet serotonin stores over days to weeks of treatment. With reduced serotonin content, platelet aggregation is impaired, compromising hemostasis. When combined with nonsteroidal anti-inflammatory drugs — which impair platelet function through cyclooxygenase-1 inhibition and reduce prostaglandin-mediated mucosal protection — the two effects are additive and substantially increase upper gastrointestinal bleeding risk. Co-prescribing a proton pump inhibitor reduces but does not eliminate this risk. Selective serotonin reuptake inhibitors do not inhibit cyclooxygenase-1 directly, do not cause vasoconstriction through submucosal serotonin effects, and do not stimulate gastric acid secretion.

Correct Answer

D — Selective serotonin reuptake inhibitors impair platelet aggregation pharmacodynamically, potentiating warfarin's effect; fluvoxamine, fluoxetine, and paroxetine also inhibit cytochrome P450 2C9 pharmacokinetically, raising warfarin plasma levels

Rationale

The antidepressant-warfarin interaction operates through two distinct and compounding mechanisms. First, all selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors impair platelet aggregation by depleting platelet serotonin stores — a pharmacodynamic effect that potentiates the anticoagulant effect of warfarin even without changing warfarin plasma concentrations. Second, fluvoxamine, fluoxetine, and paroxetine inhibit cytochrome P450 2C9, the enzyme responsible for metabolizing the more pharmacologically potent warfarin enantiomer; this pharmacokinetic effect raises warfarin plasma concentrations and the international normalized ratio directly. Citalopram and escitalopram have the least cytochrome P450 2C9 inhibitory activity among selective serotonin reuptake inhibitors and are preferred when an antidepressant is needed in a patient on warfarin. An international normalized ratio check within one to two weeks of starting or changing an antidepressant is required in all patients on warfarin. Selective serotonin reuptake inhibitors do not induce cytochrome P450 3A4 or displace warfarin from albumin.

Correct Answer

B — Sensory disturbances — particularly brain zaps — because brief electric-shock sensations spreading from the head do not occur as a manifestation of depression itself

Rationale

Among all the features of the FINISH mnemonic, sensory disturbances — specifically the brain zap phenomenon, brief electric-shock-like sensations that spread from the head through the body — are the most diagnostically distinctive. Brain zaps are not a feature of major depressive disorder and do not occur as part of depressive relapse. Their presence after antidepressant cessation strongly favors discontinuation syndrome as the diagnosis. The temporal pattern provides additional support: discontinuation syndrome begins within days of stopping and is self-limited within one to four weeks, while relapse intensifies progressively over weeks and does not self-resolve. Flu-like symptoms, insomnia, and nausea can all occur in depressive episodes as well as in discontinuation syndrome, making them less discriminating. Correctly identifying discontinuation syndrome avoids the clinical error of restarting or intensifying antidepressant treatment when the symptoms are self-limited and not indicative of worsening depression.

Correct Answer

C — Norfluoxetine — fluoxetine's active metabolite — has a very long half-life of weeks, providing a gradual pharmacokinetic self-taper as fluoxetine doses are reduced, preventing the abrupt serotonin drop that causes discontinuation symptoms

Rationale

Paroxetine has the shortest half-life among the selective serotonin reuptake inhibitors, no active metabolite, and produces the most severe discontinuation syndrome. When paroxetine is stopped or reduced, synaptic serotonin drops rapidly, triggering the FINISH symptoms. Fluoxetine produces norfluoxetine, an active metabolite with a half-life of one to three weeks, that remains present in the body long after fluoxetine itself is eliminated. Switching to fluoxetine and then reducing the fluoxetine dose exploits this long-lived metabolite — even as fluoxetine is tapered, norfluoxetine maintains serotonin reuptake transporter occupancy at progressively declining levels over weeks, executing an automatic, gradual pharmacokinetic taper that prevents the sudden serotonin deficit underlying discontinuation symptoms. This validated strategy is particularly useful for patients with severe discontinuation syndromes who cannot tolerate direct paroxetine or venlafaxine tapering despite slow schedules.

Correct Answer

A — Transient jitteriness, hypoglycemia, respiratory distress, and feeding difficulties occurring in approximately 30 percent of exposed neonates, typically resolving within two weeks without specific intervention

Rationale

Neonatal adaptation syndrome occurs in approximately 30 percent of neonates exposed to selective serotonin reuptake inhibitors in the third trimester. The features — jitteriness, hypoglycemia, mild respiratory distress, and feeding difficulties — reflect transient physiological adaptation as the neonate adjusts to the absence of the drug that was present throughout fetal development. These symptoms are transient and self-resolving within approximately two weeks in most cases without requiring specific pharmacological treatment beyond supportive care. The key clinical action is to inform the obstetric team before delivery so that the neonatal team can anticipate these findings, provide appropriate monitoring, and avoid unnecessary diagnostic workup. Neonatal adaptation syndrome should be distinguished from the rare complication of persistent pulmonary hypertension of the newborn, which has been investigated as a possible but not firmly established association with late-pregnancy selective serotonin reuptake inhibitor exposure and represents a different and more serious clinical picture.

Correct Answer

D — Selective serotonin reuptake inhibitors cause syndrome of inappropriate antidiuretic hormone secretion at several-fold higher rates in elderly patients than in younger patients, requiring baseline and four-week sodium monitoring

Rationale

Selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors can cause syndrome of inappropriate antidiuretic hormone secretion — resulting in hyponatremia — through serotonin-mediated enhancement of antidiuretic hormone release or action. This adverse effect occurs at several-fold higher rates in elderly patients than in younger adults, likely due to age-related renal and hormonal changes that reduce baseline compensatory capacity. Severe hyponatremia can cause confusion, falls, and seizures — consequences that are particularly dangerous in older patients already at elevated fall risk. Baseline sodium measurement before starting the antidepressant and a recheck at four weeks allows detection of early sodium decline before clinical symptoms develop. The mechanism is not direct renal sodium pump inhibition, additive QTc risk, or aldosterone suppression from drug accumulation.

Correct Answer

C — Tramadol's serotonin reuptake transporter inhibitory activity added to sertraline's existing blockade, producing excessive serotonergic stimulation — serotonin syndrome — with clonus as the hallmark neuromuscular finding

Rationale

Tramadol inhibits the serotonin reuptake transporter in addition to its opioid receptor agonist activity. When prescribed to a patient already on sertraline, the two drugs produce additive serotonin reuptake transporter blockade, raising synaptic serotonin to levels that overstimulate serotonin-1A and serotonin-2A receptors and precipitate serotonin syndrome. The rhythmic ankle contractions on examination are ankle clonus — the most diagnostically specific neuromuscular finding of serotonin syndrome, distinguishing it from neuroleptic malignant syndrome where lead-pipe rigidity and bradyreflexia predominate. This sertraline-tramadol combination is an underrecognized but real risk in postoperative pain management. The correct action is to stop tramadol immediately, provide supportive care and benzodiazepines, and use an alternative analgesic — morphine, hydrocodone, or oxycodone — which are pure opioid agonists without serotonin reuptake transporter activity. Tramadol does not have monoamine oxidase A inhibitory activity or alpha-1 antagonism as its mechanism in this interaction.

Correct Answer

A — Abrupt cessation of paroxetine caused rapid synaptic serotonin depletion; the electric-shock sensations (brain zaps) are the hallmark of discontinuation syndrome and do not occur as a feature of depression itself

Rationale

Paroxetine has the shortest half-life and highest discontinuation syndrome risk among the selective serotonin reuptake inhibitors. When stopped abruptly, synaptic serotonin falls rapidly — the compensatory receptor adaptations that developed over 18 months cannot adjust acutely, producing a transient functional serotonin deficiency. The brain zaps — brief electric-shock-like sensations spreading from the head — are the most distinctive feature of this syndrome and are the key finding that rules out depressive relapse, because they do not occur in depression. The time course is also characteristic: onset within days of cessation versus relapse that develops gradually over weeks. The correct response is to restart paroxetine at the prior dose — symptoms should resolve within 24 hours — then plan a gradual taper over weeks to months, or consider switching to fluoxetine to exploit norfluoxetine as a pharmacokinetic bridge. The symptoms are not explained by anticholinergic rebound excess, serotonin synthesis surge, or lagging affective relapse.

Correct Answer

D — Citalopram produces dose-dependent QTc prolongation, and the Food and Drug Administration maximum dose in patients over 60 is 20 mg per day because this risk is amplified in elderly patients; the dose should be reduced immediately

Rationale

Citalopram produces dose-dependent QTc interval prolongation — the Food and Drug Administration issued a safety communication establishing a maximum dose of 40 mg per day in most adults and 20 mg per day in patients over 60, those with hepatic impairment, and those taking cytochrome P450 2C19 inhibitors. QTc prolongation risk is amplified in elderly patients because of age-related cardiac conduction changes, polypharmacy with other QTc-prolonging agents, and electrolyte abnormalities common in this population. At 40 mg per day, this 68-year-old patient is receiving twice the recommended maximum dose for his age group. The pharmacist is correct to flag this, and the dose should be reduced to 20 mg per day promptly. Citalopram does not appear on the Beers Criteria for anticholinergic activity, is not a clinically meaningful cytochrome P450 2D6 inhibitor, and the albumin-binding concern is not the basis for this specific dose cap.

Correct Answer

B — Sertraline, because it has the lowest relative infant dose among the selective serotonin reuptake inhibitors — the infant's weight-adjusted exposure as a percentage of the maternal weight-adjusted dose is consistently low across published studies

Rationale

Sertraline is the preferred antidepressant during breastfeeding based on having the lowest relative infant dose among the selective serotonin reuptake inhibitors. Relative infant dose — defined as the infant's weight-adjusted dose as a percentage of the maternal weight-adjusted dose — is the standard measure used to assess breast milk drug transfer safety; values below 10 percent are generally considered acceptable. Sertraline consistently achieves values well below this threshold across multiple published lactation studies. Fluoxetine is generally avoided during breastfeeding because norfluoxetine, its active metabolite, has a very long half-life in neonates — a six-week-old infant has substantially reduced hepatic clearance capacity compared to adults, leading to norfluoxetine accumulation. Paroxetine also has a low relative infant dose and is an acceptable alternative, but protein binding alone is insufficient to block mammary transfer and sertraline remains the preferred first choice. Citalopram has a higher relative infant dose than sertraline.